$\square$ 

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OWR APPRC	VAL
OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

1 Indiric and Address of Reporting Leson			2. Issuer Name <b>and</b> Ticker or Trading Symbol Arbutus Biopharma Corp [ ABUS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>wiunay wian</u>	<u>KJ.</u>				Director	10% Owner			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	x	Officer (give title below)	Other (specify below)			
			06/16/2016	President & CEO					
SUITE 100, 89	00 GLENLYO	N PARKWAY		1					
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group Filir	ng (Check Applicable			
BURNABY	A1	V5J 5J8			Form filed by One Re	porting Person			
-			—		Form filed by More the Person	an One Reporting			
(City)	(State)	(Zip)		1					

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11311.4)
Common Shares	06/16/2016		X		5,000	A	\$2.5688(1)	289,389	D	


### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deri Sec Acq (A) o Disp of (I (Inst	of Expiration Date Derivative (Month/Day/Year) Securities Acquired		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrants	\$2.5688 <sup>(1)</sup>	06/16/2016		x			5,000	06/16/2011	06/16/2016	Common shares	5,000	(2)	0	D	

#### **Explanation of Responses:**

1. Exercise price of Cdn\$3.35 converted into U.S. dollars using the noon Bank of Canada exchange rate on June 16, 2016 of Cdn\$1.3041=US\$1.00.

2. The warrants were purchased as part of a private placement unit offering for Cdn\$2.85 per unit, each unit consisting of one common shares and one-half of one common share purchase warrant exercisable at Cdn\$3.35 for five years.



\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

06/20/2016